Member Info for 86KB

Nicmanc they did have cash until Q2 but they might have got offered, as some new investors wanted in so took the opportunity.

Won't be surprised if we end up flat and then blue

Getting gobbled pretty quick

Not a heavy discount like some suggested but would have thought they waited abit and done a higher price. Oh well it is what it is. Think the shares should get churned pretty quick considering meeting next week and with a stronger cash balance will be good for them come next week. Opportunity there for those looking in to buy.

The LungLB test can flip this around. In turn tapping into an addressable market, potentially worth more than $2bn pa - based on 1.5m indeterminate nodules being detected each year in the US, which are both small & relate to patients who would otherwise have had a tissue biopsy.

the business is on track to submit its Technical Assessment application (to MolDx) for Medicare coverage by the end of 2024 (re Reimbursement price of $2,030/test) – that once approved should enable first revenues to realised.

Strategically too, @LungLifeAI is in active discussions with several industry partners to help unlock the full potential of LungLB and accelerate its adoption - which if concluded would be transformational.

the business had net funds of $1.77m as at the end of Oct’24, and reiterated its cash runway guidance to Q2’25 - with several other levers to pull later if required. House broker Investec have a 171p/share target price.

Havnt really paid much attention as I know come next week we will be higher. Hold, sell, trade do what is best for you but those who have done research will know its a bargain at these levels

We are in a range at the moment once we break through that we will move higher. See where we are at come Friday.

Oh certainly all due this quarter but think semnet first. But who knows we might get a surprise rns about a new acquisition.

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules.

Our Purpose is to be a driving force in the early detection to lung cancer. And our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.

We are due the semnet news so could get rns tomorrow in regards to that

The business itself is registered in the US so surely they benefit from it

The Company was incorporated and registered under the laws of the State of Delaware, US, on 30 December 2009 as a Delaware corporation with the name Cynvenio Biosystems, Inc. The Company changed its name to LungLife AI Inc. on 1 May 2019.

The Company is domiciled in the State of Delaware, US, which is its main country of operation.

Shows how undervalued it is

Should be firmly in 2s by end of week in anticipation of deals next week.

Seems like someone is expecting news as started rising few days ago. They have diagnostic solutions which detects early cancer using AI technology and thats hot at the moment. They are looking at a strategic partner too. So news there perhaps. Plus it only as 21.32% FF so any little volume it will move quick.

Think this should do it considering where it has fallen from and if they announce the strategic partner.

Not an easy one to buy with the tiny FF. With AI stock on the rise this will get noticed

Am I right in saying they stand at £1.76?

Any idea what price the options changed to?

This must be the cheapest AI stock available with only 21.32% free float a little volume and it runs. Mcap is so low

People sell for different reasons, some are happy with their target being hit and move to next one to compound gains, nothing wrong with that. Profit is profit. You have some panic selling after listening to doom mongers and then you just get some selling as they get bored and move to the next one. They are usually the scalpers/traders.